Axion BioSystems, Inc.

Based in the US, Axion BioSystems, Inc. is a biotechnology company specializing in advanced live-cell analysis technologies that enhance understanding of human biology for disease research and therapeutic discovery. Axion BioSystems, Inc. was founded in 2008 in Atlanta, US.

The company focuses on live-cell analysis technologies without repeating products mentioned in the summary. In July 2021, it underwent a significant change when Summa Equity acquired a majority stake from GRA Venture Fund. The founder, Stephen DeWeerth, has previously been involved in founding other ventures. The company has completed 6 deals, with its latest funding round occurring on 15 July 2021, raising USD 8.

00 mn, the total amount raised being USD 8. 00 mn. Axion BioSystems specializes in advanced live-cell analysis technologies designed to provide insights into human biology, primarily for disease research and therapeutic discovery. Its core products include the Maestro series of multi-electrode array (MEA) systems, enabling real-time monitoring of electrical activity in neurons and cardiomyocytes.

The company’s offerings also include automated, AI-powered imaging solutions and impedance-based assays for tracking cellular health. Additionally, it provides automated cell counting tools for simplifying cell and organoid quantification. Axion primarily serves pharmaceutical companies, academic institutions, and contract research organizations (CROs) across North America, Europe, and Asia. Axion BioSystems generates revenue from direct sales of its live-cell analysis systems and software solutions, operating a B2B model with research institutions and pharmaceutical companies.

This includes both outright purchases and subscription agreements for software updates. The Maestro Volt is their budget-friendly option for labs with lower throughput needs, supporting diverse applications in drug discovery and cellular biology research. The pricing structure varies based on system capabilities to meet different customer needs, facilitating one-time purchases and ongoing relationships for maintenance and support. In July 2021, following the acquisition by Summa Equity, Axion BioSystems plans to enhance its technology and expand its market share, focusing on accelerating the understanding of cell behavior in drug discovery and development.

The funding from this acquisition will support the development of new products and bolster its growth strategies. The company is expected to target new markets, particularly in Europe and Asia, to broaden its reach by 2023, aligning with its goal to innovate and expand its technological capabilities.